;PMID: 10595907
;source_file_558.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..37] = [t:0..37]
;1)sentence:[e:42..158] = [t:42..158]
;2)section:[e:162..241] = [t:162..241]
;3)section:[e:245..340] = [t:245..340]
;4)sentence:[e:344..426] = [t:344..426]
;5)sentence:[e:427..579] = [t:427..579]
;6)sentence:[e:580..672] = [t:580..672]
;7)sentence:[e:673..864] = [t:673..864]
;8)sentence:[e:865..1055] = [t:865..1055]
;9)sentence:[e:1056..1144] = [t:1056..1144]
;10)sentence:[e:1145..1328] = [t:1145..1328]
;11)sentence:[e:1329..1517] = [t:1329..1517]
;12)section:[e:1521..1566] = [t:1521..1566]

;section 0 Span:0..37
;Am J Pathol  1999 Dec;155(6):1795-801
(SEC
  (FRAG (NNP:[0..2] Am) (NNP:[3..4] J) (NNP:[5..11] Pathol) (CD:[13..17] 1999)
        (.:[18..26] Dec;155-LRB-) (CD:[26..28] 6-RRB-) (CD:[28..33] :1795)
        (::[33..34] -) (CD:[34..37] 801)))

;sentence 1 Span:42..158
;Beta-catenin mutations are frequent in human hepatocellular carcinomas 
;associated with hepatitis C virus infection.
;[42..54]:gene-rna:"Beta-catenin"
;[87..157]:malignancy:"hepatocellular carcinomas  associated with hepatitis C
;virus infection"
(SENT
  (S-HLN
    (NP-SBJ (NN:[42..54] Beta-catenin) (NNS:[55..64] mutations))
    (VP (VBP:[65..68] are)
      (ADJP-PRD (JJ:[69..77] frequent))
      (PP-LOC (IN:[78..80] in)
        (NP
          (NP (JJ:[81..86] human) (JJ:[87..101] hepatocellular)
              (NNS:[102..112] carcinomas))
          (VP (VBN:[114..124] associated)
            (NP (-NONE-:[124..124] *))
            (PP-CLR (IN:[125..129] with)
              (NP
                (NML
                  (NML (NN:[130..139] hepatitis) (NN:[140..141] C))
                  (NN:[142..147] virus))
                (NN:[148..157] infection)))))))
    (.:[157..158] .)))

;section 2 Span:162..241
;Huang H, Fujii H, Sankila A, Mahler-Araujo BM, Matsuda M, Cathomas G, Ohgaki
;H.
(SEC
  (FRAG (NNP:[162..167] Huang) (NNP:[168..169] H) (,:[169..170] ,)
        (NNP:[171..176] Fujii) (NNP:[177..178] H) (,:[178..179] ,)
        (NNP:[180..187] Sankila) (NNP:[188..189] A) (,:[189..190] ,)
        (NNP:[191..197] Mahler) (::[197..198] -) (NNP:[198..204] Araujo)
        (NNP:[205..207] BM) (,:[207..208] ,) (NNP:[209..216] Matsuda)
        (NNP:[217..219] M,) (NNP:[220..228] Cathomas) (NNP:[229..230] G)
        (,:[230..231] ,) (NNP:[232..238] Ohgaki) (NNP:[239..241] H.)))

;section 3 Span:245..340
;Unit of Molecular Pathology, International Agency for Research on Cancer
;(IARC),  Lyon, France.
(SEC
  (FRAG (NNP:[245..249] Unit) (IN:[250..252] of) (NNP:[253..262] Molecular)
        (NNP:[263..272] Pathology) (,:[272..273] ,)
        (NNP:[274..287] International) (NNP:[288..294] Agency)
        (IN:[295..298] for) (NNP:[299..307] Research) (NN:[308..310] on)
        (NN:[311..317] Cancer) (-LRB-:[318..319] -LRB-) (NNP:[319..323] IARC)
        (-RRB-:[323..324] -RRB-) (,:[324..325] ,) (NNP:[327..331] Lyon)
        (,:[331..332] ,) (NNP:[333..339] France) (.:[339..340] .)))

;sentence 4 Span:344..426
;Hepatocellular carcinoma (HCC) is one of the most common fatal cancers 
;worldwide.
;[344..368]:malignancy:"Hepatocellular carcinoma"
;[370..373]:malignancy:"HCC"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[344..358] Hepatocellular) (NN:[359..368] carcinoma))
      (NP (-LRB-:[369..370] -LRB-) (NN:[370..373] HCC) (-RRB-:[373..374] -RRB-)))
    (VP (VBZ:[375..377] is)
      (NP-PRD
        (NP (CD:[378..381] one))
        (PP (IN:[382..384] of)
          (NP (DT:[385..388] the)
            (NML (RBS:[389..393] most) (JJ:[394..400] common))
            (JJ:[401..406] fatal) (NNS:[407..414] cancers))))
      (ADVP (RB:[416..425] worldwide)))
    (.:[425..426] .)))

;sentence 5 Span:427..579
;Hepatitis B virus and hepatitis C virus infections, exposure to  aflatoxin,
;and excessive intake of alcohol have been identified as major risk  factors.
(SENT
  (S
    (NP-SBJ-2
      (NP
        (NP
          (NML
            (NML (NN:[427..436] Hepatitis) (NN:[437..438] B))
            (NN:[439..444] virus))
          (NML-1 (-NONE-:[444..444] *P*)))
        (CC:[445..448] and)
        (NP
          (NML
            (NML (NN:[449..458] hepatitis) (NN:[459..460] C))
            (NN:[461..466] virus))
          (NML-1 (NNS:[467..477] infections))))
      (,:[477..478] ,)
      (NP
        (NP (NN:[479..487] exposure))
        (PP (TO:[488..490] to)
          (NP (NN:[492..501] aflatoxin))))
      (,:[501..502] ,) (CC:[503..506] and)
      (NP
        (NP (JJ:[507..516] excessive) (NN:[517..523] intake))
        (PP (IN:[524..526] of)
          (NP (NN:[527..534] alcohol)))))
    (VP (VBP:[535..539] have)
      (VP (VBN:[540..544] been)
        (VP (VBN:[545..555] identified)
          (NP-2 (-NONE-:[555..555] *))
          (PP (IN:[556..558] as)
            (NP (JJ:[559..564] major) (NN:[565..569] risk)
                (NNS:[571..578] factors))))))
    (.:[578..579] .)))

;sentence 6 Span:580..672
;However, the molecular mechanisms underlying their development are  still
;poorly understood.
(SENT
  (S
    (ADVP (RB:[580..587] However))
    (,:[587..588] ,)
    (NP-SBJ-1
      (NP (DT:[589..592] the) (JJ:[593..602] molecular)
          (NNS:[603..613] mechanisms))
      (VP (VBG:[614..624] underlying)
        (NP (PRP$:[625..630] their) (NN:[631..642] development))))
    (VP (VBP:[643..646] are)
      (ADVP (RB:[648..653] still))
      (ADVP (RB:[654..660] poorly))
      (VP (VBN:[661..671] understood)
        (NP-1 (-NONE-:[671..671] *))))
    (.:[671..672] .)))

;sentence 7 Span:673..864
;Recently, beta-catenin, one of the key components of  the Wnt signaling
;pathway, has been found to be mutated in about 20% of HCCs,  suggesting a
;role of the Wnt pathway in their development.
;[683..695]:gene-generic:"beta-catenin"
;[731..734]:gene-generic:"Wnt"
;[799..803]:malignancy:"HCCs"
;[831..834]:gene-generic:"Wnt"
(SENT
  (S
    (ADVP-TMP (RB:[673..681] Recently))
    (,:[681..682] ,)
    (NP-SBJ-1
      (NP (NN:[683..695] beta-catenin))
      (,:[695..696] ,)
      (NP
        (NP (CD:[697..700] one))
        (PP (IN:[701..703] of)
          (NP
            (NP (DT:[704..707] the) (JJ:[708..711] key)
                (NNS:[712..722] components))
            (PP (IN:[723..725] of)
              (NP (DT:[727..730] the) (NN:[731..734] Wnt)
                  (NN:[735..744] signaling) (NN:[745..752] pathway)))))))
    (,:[752..753] ,)
    (VP (VBZ:[754..757] has)
      (VP (VBN:[758..762] been)
        (VP (VBN:[763..768] found)
          (S
            (NP-SBJ-1 (-NONE-:[768..768] *))
            (VP (TO:[769..771] to)
              (VP (VB:[772..774] be)
                (VP (VBN:[775..782] mutated)
                  (NP-1 (-NONE-:[782..782] *))
                  (PP (IN:[783..785] in)
                    (NP
                      (NP
                        (QP (RB:[786..791] about) (CD:[792..794] 20))
                        (NN:[794..795] %))
                      (PP (IN:[796..798] of)
                        (NP (NNS:[799..803] HCCs)))))))))
          (,:[803..804] ,)
          (S-ADV
            (NP-SBJ (-NONE-:[804..804] *))
            (VP (VBG:[806..816] suggesting)
              (NP
                (NP (DT:[817..818] a) (NN:[819..823] role))
                (PP (IN:[824..826] of)
                  (NP (DT:[827..830] the) (NN:[831..834] Wnt)
                      (NN:[835..842] pathway))))
              (PP (IN:[843..845] in)
                (NP (PRP$:[846..851] their) (NN:[852..863] development))))))))
    (.:[863..864] .)))

;sentence 8 Span:865..1055
;In this study, we  examined beta-catenin and APC mutations in 22 HCCs
;associated with HCV  infection, using single-strand conformation polymorphism
;(SSCP) followed by  direct DNA sequencing.
;[893..905]:gene-rna:"beta-catenin"
;[910..913]:gene-rna:"APC"
;[930..965]:malignancy:"HCCs associated with HCV  infection"
(SENT
  (S
    (PP (IN:[865..867] In)
      (NP (DT:[868..872] this) (NN:[873..878] study)))
    (,:[878..879] ,)
    (NP-SBJ (PRP:[880..882] we))
    (VP (VBD:[884..892] examined)
      (NP
        (NP (NN:[893..905] beta-catenin)
          (NML-1 (-NONE-:[905..905] *P*)))
        (CC:[906..909] and)
        (NP (NN:[910..913] APC)
          (NML-1 (NNS:[914..923] mutations))))
      (PP-LOC (IN:[924..926] in)
        (NP
          (NP (CD:[927..929] 22) (NNS:[930..934] HCCs))
          (VP (VBN:[935..945] associated)
            (NP (-NONE-:[945..945] *))
            (PP-CLR (IN:[946..950] with)
              (NP (NN:[951..954] HCV) (NN:[956..965] infection))))))
      (,:[965..966] ,)
      (S-MNR
        (NP-SBJ (-NONE-:[966..966] *))
        (VP (VBG:[967..972] using)
          (NP
            (NP
              (NP
                (NML (JJ:[973..979] single) (HYPH:[979..980] -)
                     (NN:[980..986] strand))
                (NN:[987..999] conformation) (NN:[1000..1012] polymorphism))
              (NP (-LRB-:[1013..1014] -LRB-) (NN:[1014..1018] SSCP)
                  (-RRB-:[1018..1019] -RRB-)))
            (VP (VBN:[1020..1028] followed)
              (NP (-NONE-:[1028..1028] *))
              (PP (IN:[1029..1031] by)
                (NP-LGS (JJ:[1033..1039] direct) (NN:[1040..1043] DNA)
                        (NN:[1044..1054] sequencing))))))))
    (.:[1054..1055] .)))

;sentence 9 Span:1056..1144
;beta-Catenin mutations were found in nine (41%) cases,  but no APC mutations
;were found.
;[1056..1068]:gene-rna:"beta-Catenin"
;[1119..1122]:gene-rna:"APC"
(SENT
  (S
    (S
      (NP-SBJ-2 (NN:[1056..1068] beta-Catenin) (NNS:[1069..1078] mutations))
      (VP (VBD:[1079..1083] were)
        (VP (VBN:[1084..1089] found)
          (NP-2 (-NONE-:[1089..1089] *))
          (PP (IN:[1090..1092] in)
            (NP (CD:[1093..1097] nine)
              (PRN (-LRB-:[1098..1099] -LRB-)
                (NP (CD:[1099..1101] 41) (NN:[1101..1102] %))
                (-RRB-:[1102..1103] -RRB-))
              (NNS:[1104..1109] cases))))))
    (,:[1109..1110] ,) (CC:[1112..1115] but)
    (S
      (NP-SBJ-1 (DT:[1116..1118] no) (NN:[1119..1122] APC)
                (NNS:[1123..1132] mutations))
      (VP (VBD:[1133..1137] were)
        (VP (VBN:[1138..1143] found)
          (NP-1 (-NONE-:[1143..1143] *)))))
    (.:[1143..1144] .)))

;sentence 10 Span:1145..1328
;beta-Catenin immunohistochemistry revealed  nuclear accumulation of
;beta-catenin protein in all nine tumors with a  beta-catenin mutation and two
;additional tumors without a mutation.
;[1145..1157]:gene-protein:"beta-Catenin"
;[1213..1225]:gene-protein:"beta-catenin"
;[1246..1252]:malignancy:"tumors"
;[1261..1273]:gene-rna:"beta-catenin"
;[1302..1308]:malignancy:"tumors"
(SENT
  (S
    (NP-SBJ (NN:[1145..1157] beta-Catenin)
            (NN:[1158..1178] immunohistochemistry))
    (VP (VBD:[1179..1187] revealed)
      (NP
        (NP (JJ:[1189..1196] nuclear) (NN:[1197..1209] accumulation))
        (PP (IN:[1210..1212] of)
          (NP (NN:[1213..1225] beta-catenin) (NN:[1226..1233] protein))))
      (PP-LOC (IN:[1234..1236] in)
        (NP
          (NP
            (NP (DT:[1237..1240] all) (CD:[1241..1245] nine)
                (NNS:[1246..1252] tumors))
            (PP (IN:[1253..1257] with)
              (NP (DT:[1258..1259] a) (NN:[1261..1273] beta-catenin)
                  (NN:[1274..1282] mutation))))
          (CC:[1283..1286] and)
          (NP
            (NP (CD:[1287..1290] two) (JJ:[1291..1301] additional)
                (NNS:[1302..1308] tumors))
            (PP (IN:[1309..1316] without)
              (NP (DT:[1317..1318] a) (NN:[1319..1327] mutation)))))))
    (.:[1327..1328] .)))

;sentence 11 Span:1329..1517
;These  results suggest that activation of the Wnt signaling pathway by
;beta-catenin  mutation contributes significantly to the hepatocellular
;carcinogenesis  associated with HCV infection.
;[1375..1378]:gene-generic:"Wnt"
;[1400..1412]:gene-rna:"beta-catenin"
(SENT
  (S
    (NP-SBJ (DT:[1329..1334] These) (NNS:[1336..1343] results))
    (VP (VBP:[1344..1351] suggest)
      (SBAR (IN:[1352..1356] that)
        (S
          (NP-SBJ
            (NP (NN:[1357..1367] activation))
            (PP (IN:[1368..1370] of)
              (NP (DT:[1371..1374] the) (NN:[1375..1378] Wnt)
                  (NN:[1379..1388] signaling) (NN:[1389..1396] pathway)))
            (PP (IN:[1397..1399] by)
              (NP (NN:[1400..1412] beta-catenin) (NN:[1414..1422] mutation))))
          (VP (VBZ:[1423..1434] contributes)
            (ADVP (RB:[1435..1448] significantly))
            (PP-CLR (TO:[1449..1451] to)
              (NP
                (NP (DT:[1452..1455] the) (JJ:[1456..1470] hepatocellular)
                    (NN:[1471..1485] carcinogenesis))
                (VP (VBN:[1487..1497] associated)
                  (NP (-NONE-:[1497..1497] *))
                  (PP-CLR (IN:[1498..1502] with)
                    (NP (NN:[1503..1506] HCV) (NN:[1507..1516] infection))))))))))
    (.:[1516..1517] .)))

;section 12 Span:1521..1566
;PMID: 10595907 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1521..1525] PMID) (::[1525..1526] :) (CD:[1527..1535] 10595907)
        (NN:[1536..1537] -LSB-) (NNP:[1537..1543] PubMed) (::[1544..1545] -)
        (NN:[1546..1553] indexed) (IN:[1554..1557] for)
        (NNP:[1558..1566] MEDLINE-RSB-)))
